Moreno M, et al. - Researchers evaluated how long AS patients with persistent clinical remission remained flares-free after withdrawal of anti-TNF and evaluated the effects of reintroduction of treatment. In addition, they also analyzed the characteristics of subjects who did not present clinical relapse. They noted 58% of cases presenting clinical relapse during follow-up after treatment withdrawal. They found half of the patients not presenting the same clinical response which they had achieved earlier to treatment withdrawal. However, they reported the reintroduction of infliximab treatment safe.